SI3277681T1 - Imidazolonilkinolini in njihova uporaba kot inhibitorji ATM-kinaze - Google Patents
Imidazolonilkinolini in njihova uporaba kot inhibitorji ATM-kinazeInfo
- Publication number
- SI3277681T1 SI3277681T1 SI201630345T SI201630345T SI3277681T1 SI 3277681 T1 SI3277681 T1 SI 3277681T1 SI 201630345 T SI201630345 T SI 201630345T SI 201630345 T SI201630345 T SI 201630345T SI 3277681 T1 SI3277681 T1 SI 3277681T1
- Authority
- SI
- Slovenia
- Prior art keywords
- imidazolonylquinolines
- kinase inhibitors
- atm kinase
- atm
- inhibitors
- Prior art date
Links
- BAHVJMJZUDCTPT-UHFFFAOYSA-N 4-quinolin-2-ylimidazol-2-one Chemical class O=C1N=CC(C=2N=C3C=CC=CC3=CC=2)=N1 BAHVJMJZUDCTPT-UHFFFAOYSA-N 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15000968 | 2015-04-02 | ||
| EP16717560.3A EP3277681B1 (de) | 2015-04-02 | 2016-03-31 | Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren |
| PCT/EP2016/000542 WO2016155884A1 (de) | 2015-04-02 | 2016-03-31 | Imidazolonylchinoline und deren verwendung als atm kinase inhibitoren |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3277681T1 true SI3277681T1 (sl) | 2019-09-30 |
Family
ID=52814780
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201630345T SI3277681T1 (sl) | 2015-04-02 | 2016-03-31 | Imidazolonilkinolini in njihova uporaba kot inhibitorji ATM-kinaze |
| SI201631240T SI3560924T1 (sl) | 2015-04-02 | 2016-03-31 | Imidazolonilkinolini in njihova uporaba kot zaviralci ATM-kinaze |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201631240T SI3560924T1 (sl) | 2015-04-02 | 2016-03-31 | Imidazolonilkinolini in njihova uporaba kot zaviralci ATM-kinaze |
Country Status (24)
| Country | Link |
|---|---|
| US (5) | US10457677B2 (OSRAM) |
| EP (3) | EP3277681B1 (OSRAM) |
| JP (2) | JP6791873B2 (OSRAM) |
| KR (2) | KR20240044525A (OSRAM) |
| CN (3) | CN111689963A (OSRAM) |
| AU (4) | AU2016239270B2 (OSRAM) |
| BR (1) | BR122019005502B1 (OSRAM) |
| CA (1) | CA2981365A1 (OSRAM) |
| DK (2) | DK3277681T3 (OSRAM) |
| ES (3) | ES2741853T3 (OSRAM) |
| HR (2) | HRP20191396T1 (OSRAM) |
| HU (2) | HUE054745T2 (OSRAM) |
| IL (3) | IL254714B (OSRAM) |
| LT (2) | LT3277681T (OSRAM) |
| MX (2) | MX390537B (OSRAM) |
| PL (2) | PL3560924T3 (OSRAM) |
| PT (2) | PT3277681T (OSRAM) |
| RS (2) | RS59139B1 (OSRAM) |
| RU (1) | RU2743343C2 (OSRAM) |
| SG (2) | SG10202002181UA (OSRAM) |
| SI (2) | SI3277681T1 (OSRAM) |
| TR (1) | TR201911244T4 (OSRAM) |
| WO (1) | WO2016155884A1 (OSRAM) |
| ZA (1) | ZA201707423B (OSRAM) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE054745T2 (hu) * | 2015-04-02 | 2021-09-28 | Merck Patent Gmbh | Imidazolonilkinolinok és alkalmazásuk ATM-kináz-inhibitorokként |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| GB201519406D0 (en) * | 2015-11-03 | 2015-12-16 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| WO2018153365A1 (zh) * | 2017-02-27 | 2018-08-30 | 上海瑛派药业有限公司 | 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用 |
| JOP20190209A1 (ar) * | 2017-03-16 | 2019-09-12 | Astrazeneca Ab | مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان |
| JP2021510701A (ja) | 2018-01-12 | 2021-04-30 | プロリンクス エルエルシー | 併用投与の毒性を最小化するためのプロトコルおよび検証用のイメージング剤 |
| CA3093499A1 (en) | 2018-03-14 | 2019-09-19 | Merck Patent Gmbh | Compounds and uses thereof to treat tumors in a subject |
| BR112020018006A2 (pt) | 2018-04-12 | 2021-01-12 | Bayer Aktiengesellschaft | Derivados de n-(ciclopropilmetil)-5-(metilsulfonil)-n-{1-[1-(pirimidin-2-il)-1h-1,2,4-triazol-5-il]etil}benzamida e os derivados correspondentes de piridina-carboxamida como pesticidas |
| WO2019201283A1 (en) * | 2018-04-20 | 2019-10-24 | Xrad Therapeutics, Inc. | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |
| CN110386932A (zh) | 2018-04-20 | 2019-10-29 | 艾科思莱德制药公司 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
| GB201814487D0 (en) * | 2018-09-06 | 2018-10-24 | Cycle Pharmaceuticals Ltd | Cancer |
| CN109045042A (zh) * | 2018-09-21 | 2018-12-21 | 上海交通大学医学院附属上海儿童医学中心 | Atm抑制剂在制备抑制急性淋巴细胞性白血病复发的药物中的应用 |
| CN112771045B (zh) * | 2018-09-30 | 2022-04-19 | 南京明德新药研发有限公司 | 喹啉并吡咯烷-2-酮类衍生物及其应用 |
| RS65518B1 (sr) | 2019-03-27 | 2024-06-28 | Merck Patent Gmbh | Jedinjenja imidazolonilhinolina i njihova terapijska upotreba |
| CN119684291A (zh) * | 2019-07-30 | 2025-03-25 | 艾科思莱德制药公司 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
| IL292613A (en) * | 2019-11-01 | 2022-07-01 | Ares Trading Sa | Combined inhibition of pd-1, tgfβ and atm together with radiotherapy for the treatment of cancer |
| US11685734B2 (en) | 2019-12-04 | 2023-06-27 | Chdi Foundation, Inc. | ATM kinase inhibitors and compositions and methods of use thereof |
| CN115003672A (zh) * | 2020-01-09 | 2022-09-02 | 南京明德新药研发有限公司 | 喹啉并咪唑类化合物及其应用 |
| CN115380031A (zh) * | 2020-03-30 | 2022-11-22 | 南京明德新药研发有限公司 | 作为atm抑制剂的喹啉并吡咯烷-2-酮类化合物的晶型及其应用 |
| EP4168010A1 (en) * | 2020-06-18 | 2023-04-26 | Merck Patent GmbH | Compounds for the treatment of viral infections |
| US20230256110A1 (en) | 2020-06-24 | 2023-08-17 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and atm inhibitor |
| MX2023002792A (es) | 2020-09-18 | 2023-03-16 | Merck Patent Gmbh | Preparacion farmaceutica. |
| WO2022060377A1 (en) * | 2020-09-21 | 2022-03-24 | Wei Zhong | Substituted 1-(3,3-difluoropiperidin-4-yl)-imidazo[4,5-c] quinolin-2-one compounds with blood-brain barrier penetrable capability |
| EP3992191A1 (en) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors |
| CN115232122B (zh) * | 2021-04-23 | 2024-05-31 | 石药集团中奇制药技术（石家庄）有限公司 | 炔类化合物及其制备和应用 |
| CN115716829B (zh) * | 2022-11-13 | 2024-05-31 | 药康众拓(江苏)医药科技有限公司 | 一种喹啉并咪唑酮联氘代吡唑类化合物及其应用 |
| US12384808B2 (en) | 2022-11-23 | 2025-08-12 | Forward Therapeutics, Inc. | Modulators of TNF-α activity |
| WO2025157979A1 (en) | 2024-01-26 | 2025-07-31 | Merck Patent Gmbh | Synthesis route for preparing 8-(1,3-dimethyl-1h-pyrazol-4-yl)-1-(sa)-(3-fluoro-5-methoxy-pyridin-4-yl)-7-methoxy-3-methyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-one |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6221335B1 (en) * | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| DE60001623T2 (de) * | 1999-12-03 | 2003-12-18 | Pfizer Products Inc., Groton | Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel |
| GB0211649D0 (en) | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| WO2006100226A1 (en) * | 2005-03-21 | 2006-09-28 | Ferrer Internacional, S. A. | Method for making 1-substituted 1h-imidazo[4,5-c]quinolin-4-amine compounds and intermediates therefor |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| BRPI0617987A2 (pt) * | 2005-10-06 | 2011-08-16 | Auspex Pharmaceuticals Inc | composição, composição farmacêutica, forma de dosagem efervescente, composição farmacêutica oral de comprimidos unitários múltiplos, forma de dosagem farmacêutica de liberação prolongada, forma de dosagem farmacêutica revestida entérica, forma de dosagem farmacêutica estável para administração oral a sujeitos mamìferos, método para tratamento de doenças relacionadas a ácido gástrico pela inibição de secreção de ácido gástrico, método para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori, processo para preparar um composto da fórmula 3, processo para preparar um composto da fórmula 5, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relacionadas a ácido gástrico, pela inibição de secreção de ácido gástrico, uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de uma infecção bacteriana provocada ou mediada por helicobacter pylori uso de um composto da fórmula 1 para a preparação de um medicamento para tratamento de doenças relecionadas a ácido gástrico pela inibição de secreção de ácido gástrico |
| US7750168B2 (en) * | 2006-02-10 | 2010-07-06 | Sigma-Aldrich Co. | Stabilized deuteroborane-tetrahydrofuran complex |
| KR101472607B1 (ko) | 2007-02-20 | 2014-12-15 | 노파르티스 아게 | 지질 키나제 및 ｍＴＯＲ의 이중 억제제로서의 이미다조퀴놀린 |
| CA2717948C (en) | 2008-03-26 | 2016-09-06 | Novartis Ag | 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes |
| RS54560B1 (sr) | 2008-06-10 | 2016-06-30 | Abbvie Inc. | Triciklična jedinjenja |
| RU2519200C2 (ru) | 2008-10-01 | 2014-06-10 | Новартис Аг | Применение антагонистов smoothened для лечения связанных с путем hedgehog нарушений |
| AU2010255727B2 (en) | 2009-06-04 | 2013-02-28 | Novartis Ag | 1H-imidazo[4,5-c]quinolinone derivatives |
| JP2012528829A (ja) | 2009-06-04 | 2012-11-15 | ノバルティス アーゲー | １Ｈ−イミダゾ［４，５−ｃ］キノリノン化合物 |
| GB0919423D0 (en) * | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| CN102803227B (zh) * | 2010-03-16 | 2016-01-20 | 默克专利有限公司 | 吗啉基喹唑啉 |
| US8791113B2 (en) * | 2010-06-28 | 2014-07-29 | Merck Patent Gmbh | 2,4-diaryl-substituted [1,8] naphthyridines as kinase inhibitors for use against cancer |
| CN102372711B (zh) | 2010-08-18 | 2014-09-17 | 山东轩竹医药科技有限公司 | 咪唑并喹啉类PI3K和mTOR双重抑制剂 |
| DE102010035744A1 (de) | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
| CN102399218A (zh) * | 2010-09-16 | 2012-04-04 | 和记黄埔医药（上海）有限公司 | 一类并合三杂环及其作为pi3k抑制剂的用途 |
| US20130245061A1 (en) | 2010-12-03 | 2013-09-19 | Novartis Ag | Pharmaceutical compositions |
| CN103012398B (zh) | 2011-09-19 | 2015-10-14 | 上海恒瑞医药有限公司 | 咪唑并喹啉类衍生物及其可药用盐、其制备方法及其在医药上的应用 |
| WO2013154778A1 (en) | 2012-04-11 | 2013-10-17 | Dana-Farber Cancer Institute, Inc. | Host targeted inhibitors of dengue virus and other viruses |
| WO2013184621A1 (en) | 2012-06-06 | 2013-12-12 | Novartis Ag | Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease |
| NO2714752T3 (OSRAM) | 2014-05-08 | 2018-04-21 | ||
| HUE054745T2 (hu) | 2015-04-02 | 2021-09-28 | Merck Patent Gmbh | Imidazolonilkinolinok és alkalmazásuk ATM-kináz-inhibitorokként |
-
2016
- 2016-03-31 HU HUE19172903A patent/HUE054745T2/hu unknown
- 2016-03-31 DK DK16717560.3T patent/DK3277681T3/da active
- 2016-03-31 PL PL19172903T patent/PL3560924T3/pl unknown
- 2016-03-31 CN CN202010644289.6A patent/CN111689963A/zh active Pending
- 2016-03-31 ES ES16717560T patent/ES2741853T3/es active Active
- 2016-03-31 EP EP16717560.3A patent/EP3277681B1/de active Active
- 2016-03-31 EP EP19172903.7A patent/EP3560924B1/de active Active
- 2016-03-31 RS RS20190993A patent/RS59139B1/sr unknown
- 2016-03-31 KR KR1020247009513A patent/KR20240044525A/ko active Pending
- 2016-03-31 WO PCT/EP2016/000542 patent/WO2016155884A1/de not_active Ceased
- 2016-03-31 CN CN201680031887.8A patent/CN107889488B/zh active Active
- 2016-03-31 PL PL16717560T patent/PL3277681T3/pl unknown
- 2016-03-31 MX MX2020011558A patent/MX390537B/es unknown
- 2016-03-31 AU AU2016239270A patent/AU2016239270B2/en active Active
- 2016-03-31 PT PT16717560T patent/PT3277681T/pt unknown
- 2016-03-31 HR HRP20191396 patent/HRP20191396T1/hr unknown
- 2016-03-31 MX MX2017012613A patent/MX376947B/es active IP Right Grant
- 2016-03-31 LT LTEP16717560.3T patent/LT3277681T/lt unknown
- 2016-03-31 US US15/563,680 patent/US10457677B2/en active Active
- 2016-03-31 BR BR122019005502-5A patent/BR122019005502B1/pt active IP Right Grant
- 2016-03-31 SG SG10202002181UA patent/SG10202002181UA/en unknown
- 2016-03-31 TR TR2019/11244T patent/TR201911244T4/tr unknown
- 2016-03-31 KR KR1020177031770A patent/KR102652052B1/ko active Active
- 2016-03-31 ES ES21165573T patent/ES2946507T3/es active Active
- 2016-03-31 RS RS20210817A patent/RS62082B1/sr unknown
- 2016-03-31 CN CN202010644109.4A patent/CN111747952A/zh active Pending
- 2016-03-31 EP EP21165573.3A patent/EP3868761B1/de active Active
- 2016-03-31 ES ES19172903T patent/ES2880626T3/es active Active
- 2016-03-31 SI SI201630345T patent/SI3277681T1/sl unknown
- 2016-03-31 RU RU2017138100A patent/RU2743343C2/ru active
- 2016-03-31 JP JP2017551589A patent/JP6791873B2/ja active Active
- 2016-03-31 CA CA2981365A patent/CA2981365A1/en active Pending
- 2016-03-31 DK DK19172903.7T patent/DK3560924T3/da active
- 2016-03-31 SI SI201631240T patent/SI3560924T1/sl unknown
- 2016-03-31 PT PT191729037T patent/PT3560924T/pt unknown
- 2016-03-31 LT LTEP19172903.7T patent/LT3560924T/lt unknown
- 2016-03-31 SG SG11201708065QA patent/SG11201708065QA/en unknown
- 2016-03-31 HU HUE16717560A patent/HUE045477T2/hu unknown
-
2017
- 2017-09-26 IL IL254714A patent/IL254714B/en active IP Right Grant
- 2017-11-01 ZA ZA2017/07423A patent/ZA201707423B/en unknown
-
2019
- 2019-03-14 US US16/353,559 patent/US10745399B2/en active Active
- 2019-12-17 IL IL271494A patent/IL271494B/en active IP Right Grant
-
2020
- 2020-06-24 US US16/910,438 patent/US10975075B2/en active Active
- 2020-06-25 AU AU2020204241A patent/AU2020204241B2/en active Active
- 2020-11-05 JP JP2020185129A patent/JP7111790B2/ja active Active
-
2021
- 2021-03-17 US US17/204,619 patent/US11608338B2/en active Active
- 2021-04-22 IL IL282584A patent/IL282584B/en unknown
- 2021-06-23 HR HRP20210981TT patent/HRP20210981T1/hr unknown
-
2022
- 2022-10-21 AU AU2022256215A patent/AU2022256215A1/en not_active Abandoned
-
2023
- 2023-03-01 US US18/116,094 patent/US20230203034A1/en active Pending
-
2025
- 2025-01-20 AU AU2025200385A patent/AU2025200385A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3277681T (pt) | Imidazolinilquinolinas e a sua utilização como inibidores da cinase atm | |
| IL279258B (en) | tyrosine kinase inhibitors | |
| EP3171874A4 (en) | Imidazolyl kinase inhibitors and uses thereof | |
| PL3380479T3 (pl) | Triazolowe inhibitory acc i ich zastosowania | |
| SG10201913927VA (en) | Kinase inhibitors and uses thereof | |
| GB201605126D0 (en) | Inhibitors and their uses | |
| IL259150B (en) | Pyrimidine derivative and use thereof | |
| ZA201700021B (en) | Alk kinase inhibitor, and preparation method and use thereof | |
| IL254916B (en) | Inhibitors and their uses | |
| IL251077A0 (en) | Integrin inhibitors and their use | |
| PT3719021T (pt) | Inibidores da cinase 1 associada a adaptador, composições compreendendo estes, e métodos da sua utilização | |
| IL251078B (en) | Integrin inhibitors and their use | |
| IL258690A (en) | Pyridone derivatives and their use as kinase inhibitors | |
| GB201505971D0 (en) | Inhibitors and their uses | |
| GB201505975D0 (en) | Inhibitors and their uses | |
| GB201509381D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201505460D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB2545167B (en) | Cloches and use thereof | |
| GB201519381D0 (en) | Kinase inhibitors | |
| GB201519382D0 (en) | Kinase inhibitors | |
| GB201609580D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201409661D0 (en) | Novel compounds and their use as kinase inhibitors | |
| GB201405532D0 (en) | Novel compounds and their use as Kinase inhibitors |